FDA delays approval of Bristol-Myers' belatacept

05/2/2010 | Reuters

Bristol-Myers Squibb has received a complete-response letter from the FDA for its kidney-transplant drug belatacept. The agency asked for additional data on the long-term effects of the treatment as well as the company's risk evaluation and mitigation plan for the product.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT